SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 12/14/2017 1:26:47 PM - Followers: 194 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

SureTrader
Interactive Brokers Advertisement
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Current Report Filing (8-k) 12/12/2017 01:01:12 PM
CVM News: Amended Quarterly Report (10-q/a) 12/11/2017 04:42:56 PM
CVM News: Amended Quarterly Report (10-q/a) 12/11/2017 04:41:10 PM
CVM News: Amended Quarterly Report (10-q/a) 12/11/2017 04:40:17 PM
CVM News: Amended Annual Report (10-k/a) 12/11/2017 04:38:57 PM
PostSubject
#12120  Sticky Note CEL-SCI Granted European Patent for Multikine’s Mechanism of trickledownfacists 10/10/17 08:40:02 AM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#12338   At Clinicaltrial they don't say 10% of OS lux1 12/14/17 01:26:47 PM
#12337   Thank you Montana, I agree with the article, lux1 12/14/17 11:16:29 AM
#12336   Affirm trickledownfacists 12/14/17 11:04:46 AM
#12335   The standard of care has been improving, during Montana Cabin 12/14/17 10:43:56 AM
#12334   Do you think their guess about patients not Trustbaby 12/14/17 10:16:46 AM
#12333   Excellent article from last year. Foxwoods Man 12/14/17 09:50:08 AM
#12332   This article gives a possible explanation, for the Montana Cabin 12/14/17 09:36:53 AM
#12331   What was the purpose of "when they wanted Trustbaby 12/14/17 07:51:56 AM
#12330   There are companies that survive on trials for lux1 12/14/17 04:51:02 AM
#12329   During the clinical hold their is sea alice 12/13/17 10:51:46 PM
#12328   Yes. The doctors know who is getting trickledownfacists 12/13/17 06:42:37 PM
#12327   I remember reading very clearly that this was lightrock 12/13/17 06:41:19 PM
#12326   Correct. i only mentioned it because of this: Foxwoods Man 12/13/17 02:12:43 PM
#12325   I have had that argument with someone who Montana Cabin 12/13/17 01:23:58 PM
#12324   That can be said about any insider buys Trustbaby 12/13/17 09:54:36 AM
#12323   Wouldn't that be considered trading on info not Foxwoods Man 12/13/17 09:51:45 AM
#12322   Of course he did. He wouldn't have invested Trustbaby 12/13/17 09:34:22 AM
#12321   let's get serious, Geert always perfectly knew the lux1 12/12/17 06:27:38 PM
#12320   Thanks Trickle! warfaretrader 12/12/17 05:30:01 PM
#12319   They are done treating patients so costs have plummeted. trickledownfacists 12/12/17 05:02:50 PM
#12318   They have $1.5 million left trickledownfacists 12/12/17 05:01:19 PM
#12317   CVM has got to be running on Fume$$$ warfaretrader 12/12/17 04:43:24 PM
#12316   Only 1050 shares though trickle. Hopefully that warfaretrader 12/11/17 08:46:09 PM
#12315   I would think that would be "material" if lightrock 12/11/17 07:35:42 PM
#12314   yeah, "Ready ! Fire ! Aim !" lightrock 12/11/17 07:26:43 PM
#12313   Coiled Spring Mtzzz 12/11/17 07:25:36 PM
#12312   $1.98 after hours trickledownfacists 12/11/17 06:10:41 PM
#12311   Affirm :) Trustbaby 12/11/17 04:06:45 PM
#12310   Also said we are very close to arbitration finish trickledownfacists 12/11/17 04:05:37 PM
#12309   He also said that we were very close Trustbaby 12/11/17 04:01:29 PM
#12308   Geert at the Rodman & Renshaw presentation (Sept.) Montana Cabin 12/11/17 03:51:36 PM
#12307   what is strange is this phrase on Clinicaltrials lux1 12/11/17 02:57:08 PM
#12306   https://www.businesswire.com/news/home/20171211005938/en/CEL-SCI-Reaches-Full-En trickledownfacists 12/11/17 02:26:04 PM
#12305   A Company behavior not easy to be understood. lux1 12/11/17 02:07:45 PM
#12304   CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 trickledownfacists 12/11/17 01:37:55 PM
#12303   The Clinical Trials site was updated on 12/8 Foxwoods Man 12/11/17 08:13:41 AM
#12302   Not sure how to interpret that either mikedel. drkazmd65 12/11/17 07:27:44 AM
#12301   From clinicaltrials.gov the final data was collected in mikedel 12/11/17 07:22:19 AM
#12300   That is interesting. Keep in mind that drkazmd65 12/10/17 11:13:27 AM
#12299   No clue Foxwoods Man 12/10/17 11:06:00 AM
#12298   Are you sure they don't already have the Trustbaby 12/10/17 09:49:44 AM
#12297   That was my point earlier this week when Foxwoods Man 12/10/17 05:08:24 AM
#12296   Yes. Ergomed's last financial report said they trickledownfacists 12/10/17 01:09:31 AM
#12295   Anyone notice this on the Clinical Trials . Trustbaby 12/09/17 11:24:47 PM
#12294   And what would be proprietary about that? learning curve 12/09/17 06:25:48 PM
#12293   https://m.youtube.com/watch?v=GT83IAuOhGU trickledownfacists 12/09/17 03:56:49 PM
#12292   Very interesting is that the mixture of Leucocyte lux1 12/08/17 02:01:31 PM
#12291   Lux, I noticed that, about a week ago. If Montana Cabin 12/08/17 12:41:56 PM
#12290   likely not rocket science here, but Interleukins are lux1 12/08/17 12:28:32 PM
#12289   Crazy low market cap for a biotech in Mtzzz 12/08/17 12:05:20 PM
PostSubject